Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CTXR
CTXR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CTXR News
LYMPHIR Shows Promise in Gynecologic Cancer Treatment
13h ago
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
6d ago
PRnewswire
Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL
6d ago
Newsfilter
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
Feb 13 2026
PRnewswire
Citius Oncology Reports $3.9 Million in Initial Sales Revenue
Feb 13 2026
PRnewswire
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
Dec 27 2025
Yahoo Finance
U.S. Stocks Rise with Dow Jones Surging Over 200 Points
Dec 24 2025
Benzinga
U.S. Initial Jobless Claims Drop to 214,000, Beating Estimates
Dec 24 2025
Benzinga
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million
Dec 24 2025
Benzinga
Citius Pharmaceuticals Launches LYMPHIR, Stock Surges 22.12%
Dec 24 2025
Benzinga
UiPath to Replace Synovus in S&P MidCap 400 Effective January 2, 2026
Dec 24 2025
Benzinga
Citius Oncology Launches LYMPHIR, Completes $36 Million Financing
Dec 23 2025
Newsfilter
Citius Oncology Reports $0.34 Loss Per Share for Fiscal Year Ending September 30
Dec 23 2025
Yahoo Finance
Citius Oncology Launches LYMPHIR™ Cancer Immunotherapy with Market Potential Exceeding $400 Million
Dec 23 2025
PRnewswire
Citius Oncology Launches LYMPHIR, Completes $36 Million Financing
Dec 23 2025
PRnewswire
Citius Oncology Closes $18 Million Financing to Support LYMPHIR Launch
Dec 10 2025
Newsfilter
Show More News
